Bb Biotech Ag is an investment fund managing more than $3.98 billion ran by Ivo Betschart. There are currently 35 companies in Mr. Betschart’s portfolio. The largest investments include Ionis Pharmaceuticals and Incyte, together worth $938 million.
As of 7th October 2020, Bb Biotech Ag’s top holding is 7,725,000 shares of Ionis Pharmaceuticals currently worth over $627 million and making up 15.8% of the portfolio value.
Relative to the number of outstanding shares of Ionis Pharmaceuticals, Bb Biotech Ag owns less than approximately 0.1% of the company.
In addition, the fund holds 3,620,000 shares of Incyte worth $311 million, whose value grew 6.4% in the past six months.
The third-largest holding is Neurocrine Biosciences worth $297 million and the next is Vertex Pharmaceuticals worth $239 million, with 1,300,000 shares owned.
Currently, Bb Biotech Ag's portfolio is worth at least $3.98 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Bb Biotech Ag office and employees reside in Schaffhausen, Switzerland. According to the last 13-F report filed with the SEC, Ivo Betschart serves as the SIGNING AUTHORITY at Bb Biotech Ag.
In the most recent 13F filing, Bb Biotech Ag revealed that it had opened a new position in
CRISPR Therapeutics AG and bought 810,462 shares worth $29 million.
This means they effectively own approximately 0.1% of the company.
CRISPR Therapeutics AG makes up
0.8%
of the fund's Health Care sector allocation and has grown its share price by 181.0% in the past year.
The investment fund also strengthened its position in Neurocrine Biosciences by buying
23,696 additional shares.
This makes their stake in Neurocrine Biosciences total 3,366,786 shares worth $297 million.
Neurocrine Biosciences soared 11.5% in the past year.
On the other hand, there are companies that Bb Biotech Ag is getting rid of from its portfolio.
Bb Biotech Ag closed its position in Regeneron Pharmaceuticals on 13th May 2019.
It sold the previously owned 68,156 shares for $25.5 million.
Ivo Betschart also disclosed a decreased stake in Ionis Pharmaceuticals by 0.1%.
This leaves the value of the investment at $627 million and 7,725,000 shares.
The two most similar investment funds to Bb Biotech Ag are Sculptor Capital L.P. and Boston Trust & Investment. They manage $3.98 billion and $3.95 billion respectively.
Bb Biotech Ag’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 92.5% of
the total portfolio value.
The fund focuses on investments in the United States as
80.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
20% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $9.87 billion.
These positions were updated on May 13th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ionis Pharmaceuticals, Inc. |
11.63%
7,725,000
|
$627,038,000 | 15.76% |
| Incyte Corp. |
4.95%
3,620,000
|
$311,356,000 | 7.83% |
| Neurocrine Biosciences, Inc. |
0.71%
3,366,786
|
$296,614,000 | 7.46% |
| Vertex Pharmaceuticals, Inc. |
5.14%
1,300,000
|
$239,135,000 | 6.01% |
| SAGE Therapeutics, Inc. |
No change
1,375,229
|
$218,730,000 | 5.50% |
| Celgene Corp |
4.51%
2,200,000
|
$207,548,000 | 5.22% |
| Agios Pharmaceuticals, Inc. |
3.47%
2,978,134
|
$200,845,000 | 5.05% |
| Alexion Pharmaceuticals, Inc. |
No change
1,314,428
|
$177,684,000 | 4.47% |
| Alnylam Pharmaceuticals, Inc. |
3.80%
1,631,089
|
$152,425,000 | 3.83% |
| Esperion Therapeutics, Inc. |
3.83%
3,522,964
|
$141,447,000 | 3.56% |
| Radius Health, Inc. |
1.06%
6,781,685
|
$135,227,000 | 3.40% |
| Halozyme Therapeutics, Inc. |
No change
8,322,860
|
$133,998,000 | 3.37% |
| argenx SE |
2.26%
904,739
|
$112,948,000 | 2.84% |
| Moderna, Inc. |
No change
4,785,681
|
$97,389,000 | 2.45% |
| Myovant Sciences Ltd. |
No change
3,597,882
|
$85,881,000 | 2.16% |
| Intercept Pharmaceuticals, Inc. |
21.06%
696,976
|
$77,964,000 | 1.96% |
| Gilead Sciences, Inc. |
14.26%
1,142,204
|
$74,255,000 | 1.87% |
| Nektar Therapeutics |
46.32%
2,020,676
|
$67,895,000 | 1.71% |
| Exelixis, Inc. |
No change
2,835,000
|
$67,473,000 | 1.70% |
| Akcea Therapeutics, Inc. |
0.37%
2,377,638
|
$67,358,000 | 1.69% |
| MyoKardia, Inc. |
44.19%
1,264,913
|
$65,763,000 | 1.65% |
| MacroGenics, Inc. |
3.56%
3,400,000
|
$61,132,000 | 1.54% |
| Wave Life Sciences Ltd. |
No change
1,465,002
|
$56,915,000 | 1.43% |
| Voyager Therapeutics, Inc. |
No change
2,865,841
|
$54,852,000 | 1.38% |
| Audentes Therapeutics, Inc. |
78.01%
1,369,604
|
$53,442,000 | 1.34% |
| Alder Biopharmaceuticals Inc. |
No change
2,766,008
|
$37,756,000 | 0.95% |
| CRISPR Therapeutics AG |
Opened
810,462
|
$28,950,000 | 0.73% |
| Scholar Rock Holding Corp. |
15.38%
1,476,839
|
$27,750,000 | 0.70% |
| Intra-Cellular Therapies, Inc. |
No change
2,200,000
|
$26,796,000 | 0.67% |
| Regeneron Pharmaceuticals, Inc. |
Closed
68,156
|
$25,456,000 | |
| Sangamo Therapeutics, Inc. |
96.30%
2,650,000
|
$25,281,000 | 0.64% |
| Kezar Life Sciences, Inc. |
49.13%
1,220,503
|
$21,652,000 | 0.54% |
| G1 Therapeutics, Inc. |
No change
671,925
|
$11,154,000 | 0.28% |
| Cidara Therapeutics, Inc. |
No change
2,295,272
|
$6,082,000 | 0.15% |
| Novavax, Inc. |
No change
8,330,000
|
$4,589,000 | 0.12% |
| Homology Medicines, Inc. |
Opened
91,336
|
$2,533,000 | 0.06% |
| No transactions found | |||
| Showing first 500 out of 36 holdings | |||